Risk score (number of SNPs in risk score) | Body mass indexc | Total fat massc,d,e | Android/gynoid ratioc,d,e | Preperitoneal fat areac,d,e | ||||
---|---|---|---|---|---|---|---|---|
Beta (CI 95Â %) | P-value | Beta (CI 95Â %) | P-value | Beta (CI 95Â %) | P-value | Beta (CI 95Â %) | P-value | |
Main risk scores* | ||||||||
 Adult BMI (N = 97) | 0.112 (0.084; 0.141) | 1.01*10 −14 | 0.092 (0.065; 0.119) | 3.89*10 −11 | 0.077 (0.045; 0.108) | 2.00*10 −6 | 0.034 (0.001; 0.066) | 0.042 |
 Secondary risk scores | ||||||||
 Adult WHR (N = 47) | −0.012 (−0.042; 0.017) | 0.405 | −0.012 (−0.040 0.016) | 0.402 | 0.073 (0.041; 0.105) | 8.00*10 −6 | 0.029 (−0.004; 0.061) | 0.088 |
 Child BMI (N = 15) | 0.091 (0.063; 0.119) | 3.43*10 −10 | 0.073 (0.046; 0.100) | 1.40*10 −7 | 0.081 (0.050; 0.112) | 3.75*10 −7 | 0.038 (0.006; 0.070) | 0.020 |
Adult BMI pathway genetic risk scores** | ||||||||
Neuronal | ||||||||
 Neuronal developmental processes (N = 29) | 0.018 (0.014; 0.023) | 2.25*10-5 | 0.032 (0.003; 0.061) | 0.031 | 0.038 (0.004; 0.071) | 0.029 | 0.008 (−0.026; 0.042) | 0.654 |
 Neurotransmission (N = 10) | 0.013 (−0.015; 0.042) | 0.370 | −0.003 (−0.030; 0.024) | 0.827 | 0.002 (−0.029; 0.034) | 0.876 | −0.009 (−0.040; 0.023) | 0.595 |
 Hypothalamic expression and regulation (N = 13) | 0.099 (0.071; 0.128) | 5.81*10 −12 | 0.089 (0.062; 0.115) | 1.29*10 −10 | 0.080 (0.049; 0.111) | 5.30*10 −7 | 0.041 (0.009; 0.073) | 0.013 |
 Neuronal expression (N = 12) | 0.017 (−0.012; 0.046) | 0.240 | 0.020 (−0.008; 0.047) | 0.165 | 0.036 (0.004; 0.068) | 0.027 | 0.009 (−0.023; 0.041) | 0.583 |
0.023 (−0.005; 0.052) | 0.112 | 0.013 (−0.014; 0.041) | 0.341 | 0.016 (−0.016; 0.048) | 0.320 | −0.001 (−0.033; 0.032) | 0.972 | |
 Bone development (N = 9) | 0.018 (−0.011; 0.064) | 0.226 | 0.006 (−0.021; 0.033) | 0.656 | 0.015 (−0.016; 0.047) | 0.340 | 0.004 (−0.028; 0.036) | 0.811 |
Signaling | ||||||||
 MAPK1/extracellular signal-regulated kinases (N = 9) | 0.034 (0.006; 0.062) | 0.018 | 0.037 (0.010; 0.064) | 0.008 | 0.023 (−0.008; 0.054) | 0.149 | 0.014 (−0.017; 0.046) | 0.378 |
 JAK (N = 2) | 0.033 (0.005; 0.062) | 0.023 | 0.020 (−0.007; 0.047) | 0.150 | 0.012 (−0.020; 0.043) | 0.457 | 0.007 (−0.025; 0.039) | 0.676 |
 CyclicAMP (N = 5) | 0.046 (0.017; 0.075) | 0.002 | 0.052 (0.024; 0.079) | 2.75*10 −4 | 0.039 (0.006; 0.071) | 0.019 | 0.026 (−0.007; 0.058) | 0.123 |
 WNTSignaling (N = 6) | 0.058 (0.030; 0.087) | 6.10*10 −5 | 0.029 (0.002; 0.057) | 0.034 | 0.039 (0.007; 0.070) | 0.016 | 0.032 (0.000; 0.064) | 0.047 |
G-protein coupled receptor | ||||||||
 Notch signaling (N = 2) | −0.027 (−0.056; 0.001) | 0.059 | −0.028 (−0.055; 0.000) | 0.046 | −0.028 (−0.059; 0.003) | 0.075 | −0.028 (−0.060; 0.003) | 0.080 |
 Mitochondrial (N = 8) | 0.040 (0.010; 0.070) | 0.009 | 0.041 (0.012; 0.069) | 0.005 | −0.002 (−0.035; 0.031) | 0.905 | −0.003 (−0.037; 0.031) | 0.877 |
 Retinoic acid receptors (N = 6) | 0.045 (0.017; 0.074) | 0.002 | 0.037 (0.010; 0.065) | 0.007 | 0.016 (−0.015; 0.047) | 0.313 | 0.017 (−0.015; 0.049) | 0.293 |
 Endocytosis/exocytosis (N = 14) | −0.012 (−0.041; 0.016) | 0.400 | −0.003 (−0.030; 0.024) | 0.840 | −0.021 (−0.053; 0.010) | 0.178 | −0.020 (−0.051; 0.012) | 0.218 |
 Eye-related (N = 5) | 0.012 (−0.016; 0.041) | 0.398 | 0.015 (−0.012; 0.043) | 0.276 | −0.012 (−0.044; 0.020) | 0.456 | 0.003 (−0.029; 0.035) | 0.845 |
 Tumorigenesis (N = 11) | 0.041 (0.012; 0.070) | 0.006 | 0.020 (−0.008; 0.048) | 0.161 | 0.017 (−0.016; 0.049) | 0.312 | 0.013 (−0.020; 0.046) | 0.431 |
 Apoptosis (N = 13) | 0.025 (−0.003; 0.054) | 0.084 | 0.020 (−0.007; 0.047) | 0.151 | −0.008 (−0.039; 0.024) | 0.621 | −0.036 (−0.068; −0.004) | 0.028 |
 Membrane proteins (N = 12) | 0.075 (0.046; 0.103) | 2.44*10 −7 | 0.044 (0.017; 0.071) | 0.002 | 0.059 (0.028; 0.090) | 1.93*10 −4 | 0.011 (−0.021; 0.044) | 0.495 |
 Hormone metabolism/regulation (N = 4) | 0.021 (−0.008; 0.049) | 0.161 | 0.043 (0.015; 0.070) | 0.002 | 0.026 (−0.005; 0.057) | 0.103 | 0.004 (−0.028; 0.036) | 0.812 |
 Purine/pyrimidine cycle (N = 4) | 0.013 (−0.016; 0.041) | 0.379 | 0.004 (−0.023; 0.031) | 0.762 | −0.017 (−0.048; 0.014) | 0.285 | −0.007 (−0.038; 0.024) | 0.661 |
 Monogenic obesity/energy homeostasis (N = 9) | 0.074 (0.045; 0.102) | 4.74*10 −7 | 0.068 (0.041; 0.095) | 1.00*10 −6 | 0.065 (0.034; 0.096) | 5.00*10 −5 | 0.030 (−0.003; 0.062) | 0.072 |
 Immune system (N = 15) | 0.045 (0.017; 0.074) | 0.002 | 0.037 (0.010; 0.065) | 0.008 | 0.021 (−0.011; 0.052) | 0.193 | −0.008 (−0.040; 0.024) | 0.620 |
 Limb development (N = 3) | 0.035 (0.007; 0.064) | 0.015 | 0.024 (−0.006; 0.049) | 0.125 | 0.028 (−0.003; 0.060) | 0.076 | 0.004 (−0.028; 0.036) | 0.794 |
 Ubiquitin pathways (N = 6) | −0.007 (−0.036; 0.021) | 0.617 | 0.006 (−0.021; 0.034) | 0.656 | −0.011 (−0.043; 0.020) | 0.483 | −0.015 (−0.047; 0.017) | 0.359 |
 Glucose homeostasis/diabetes (N = 11) | 0.050 (0.021; 0.079) | 0.001 | 0.023 (−0.004; 0.051) | 0.096 | 0.042 (0.011; 0.074) | 0.008 | 0.009 (−0.023; 0.042) | 0.575 |
 Cell cycle (N = 23) | 0.044 (0.016; 0.073) | 0.002 | 0.047 (0.019; 0.074) | 0.001 | 0.024 (−0.007; 0.055) | 0.135 | 0.007 (−0.025; 0.039) | 0.684 |
DNARepair | ||||||||
 Nuclear trafficking (N = 4) | −0.005 (−0.034; 0.023) | 0.716 | −0.009 (−0.036; 0.018) | 0.518 | −0.004 (−0.036; 0.028) | 0.804 | −0.008 (−0.041; 0.024) | 0.608 |
 Muscle biology (N = 6) | 0.048 (0.020; 0.077) | 0.001 | 0.029 (0.002; 0.057) | 0.038 | 0.025 (−0.007; 0.056) | 0.127 | 0.022 (−0.010; 0.054) | 0.181 |